Tobias Walbert
Overview
Explore the profile of Tobias Walbert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
1761
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rendo V, Lee E, Bossi C, Khuu N, Rudek M, Pal S, et al.
Sci Transl Med
. 2025 Feb;
17(786):eadn6274.
PMID: 39970230
Inhibitors of murine double minute homolog 2 (MDM2) represent a promising therapeutic approach for the treatment of wild-type glioblastomas (GBMs), reactivating p53 signaling to induce cancer cell death. We conducted...
2.
Boele F, Hertler C, Sherwood P, Cachia D, Dirven L, Young J, et al.
Neurooncol Pract
. 2025 Feb;
12(1):19-33.
PMID: 39917763
Background: Family caregivers in neuro-oncology (eg, spouse, family member, friend to a patient) have high unmet support needs, yet intervention trials and effective support options are scarce. The Response Assessment...
3.
Fortunato J, Walsh L, Polacek L, Reiner A, Walbert T, Thomas A, et al.
Neurooncol Pract
. 2025 Feb;
12(1):100-112.
PMID: 39917760
Background: Patients with glioblastoma (GBM) often have inaccurate perceptions of prognosis. Strong religious beliefs have been associated with limited illness understanding (IU) in patients with advanced cancer, but IU and...
4.
Khalili B, Walbert T, Horbinski C, Dixit K, Gururangan K, Thio H, et al.
Future Oncol
. 2025 Jan;
21(4):483-491.
PMID: 39786974
Seizures are a frequent complication in glioma. Incidence of brain tumor-related epilepsy (BTRE) in high-grade glioma (HGG) is an estimated > 25% and in low-grade glioma (LGG) is approximately 72%....
5.
Walbert T, Avila E, Boele F, Hertler C, Lu-Emerson C, van der Meer P, et al.
Neurooncol Pract
. 2025 Jan;
12(Suppl 1):i38-i48.
PMID: 39776527
According to the 2021 World Health Organization classification of CNS tumors, gliomas harboring a mutation in isocitrate dehydrogenase (mIDH) are considered a distinct disease entity, typically presenting in adult patients...
6.
Mendez J, Cohen A, Eckenstein M, Jensen R, Burt L, Salzman K, et al.
Neurooncol Adv
. 2024 Dec;
6(1):vdae202.
PMID: 39734810
Background: Glioblastoma (GBM) has a median survival of <2 years. Pexidartinib (PLX3397) is a small-molecule inhibitor of CSF1R, KIT, and oncogenic FTL3, which are implicated in GBM treatment resistance. Results...
7.
Walbert T, Schultz L, Mikkelsen T, Snyder J, Phillips J, Fortunato J
Neurooncol Pract
. 2024 Nov;
11(6):733-739.
PMID: 39554791
Background: Glioblastoma and high-grade glioma (HGG) remain non-curable diseases. Symptoms and Quality-of-life (QoL) in the end-of-life (EoL) phase have not been prospectively studied with validated instruments. Therefore, we prospectively assessed...
8.
Moertel C, Hirbe A, Shuhaiber H, Bielamowicz K, Sidhu A, Viskochil D, et al.
J Clin Oncol
. 2024 Nov;
43(6):716-729.
PMID: 39514826
Purpose: Pharmacologic therapies for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs) are limited; currently, none are US Food and Drug Administration-approved for adults. Methods: ReNeu is an open-label, multicenter, pivotal, phase...
9.
Holdhoff M, Ye X, Strowd R, Nabors B, Walbert T, Lieberman F, et al.
Neurooncol Adv
. 2024 Oct;
6(1):vdae150.
PMID: 39371261
Background: Lisavanbulin (BAL101553) is a small, lipophilic, oral microtubule destabilizer with promising antitumoral activity observed in preclinical glioblastoma (GBM) models. Methods: This multicenter phase 1 study sought to determine the...
10.
Rendo V, Lee E, Bossi C, Khuu N, Rudek M, Pal S, et al.
medRxiv
. 2024 Aug;
PMID: 39211865
Statement Of Significance: Tissue sampling during this clinical trial allowed us to assess mechanisms of response and resistance associated with navtemadlin treatment in recurrent GBM. We report that clinically achievable...